Baxter Clindamycin Injection Recall Over CGMP Deviations (Aug 6, 2026, 00:00 UTC)
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Baxter Healthcare Corporation is recalling one lot of Clindamycin Injection USP in 5% Dextrose due to CGMP deviations.
The full picture behind this FDA recall
This notice was issued by FDA on September 14, 2026 and geographically references United States, Puerto Rico, Chile. The FDA classifies this as a Class II recall, with the stated reason "CGMP Deviations", distributed us nationwide; puerto rico; and chile.. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
A quick skim tells you whether this affects you directly; a closer read tells you more. Check the scope, the source, and how recent the record is, then weigh it against related notices rather than treating any single one as a trend.
The original agency source is linked below so you can verify this record directly before acting on it. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Baxter Healthcare Corporation initiated a voluntary recall due to CGMP deviations.
Which Products Are Affected
Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic. NDC 43066-995-24. Lot # NC194068, Exp Date: 10/29/2027. Distributed to US Nationwide, Puerto Rico, and Chile.
What You Should Do
The recall was initiated by letter. No additional consumer instructions are provided in the recall data.
Why This Matters
This is an ongoing Class II recall affecting prescription intravenous medication distributed across multiple regions.
Source
FDA Enforcement Report, recall number D-0818-2026, Baxter Healthcare Corporation, Deerfield, IL.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Medline Convenience Kits Recall Over ChloraPrep Applicator Sterility Breach (Ref. 2fe0d4)
FDA · September 16, 2026
Cardinal Health Presource Packs Recall Over CliniClean Pericare Wipes Contamination (Ref. 1adab6)
FDA · September 16, 2026
Medline Convenience Kits Recall Over BD ChloraPrep Applicator Seal Issue (Ref. 929d71)
FDA · September 16, 2026
Nationwide notices with similar length or severity timing 8
Beyond this FDA recall's own category, Areazine surfaces two nationwide peer sets: length-matched and severity/date-matched notices from elsewhere in the archive, distinct from the same-feed Related list above.
Similar body length
Nearest notices by article body length (753 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to September 14, 2026.
Common Questions
Common questions about this FDA recall.